The World Health Organization’s South-East Asia Region (SEARO) has reaffirmed its commitment to maintaining polio-free status, marking a decade since the last indigenous case of wild poliovirus was reported in 2011. With 11 member countries—including India, Indonesia, and Bangladesh—now certified free of wild polio, officials emphasize sustained surveillance and vaccination efforts to prevent reintroduction from high-risk regions like Pakistan and Afghanistan. The announcement comes amid rising global concern over vaccine-derived poliovirus (VDPV) outbreaks, which require targeted oral polio vaccine (OPV) campaigns to contain.
Why this matters: Polio eradication remains one of the most complex public health achievements in history, but the fight isn’t over. While wild polio has been eliminated in SEARO, vaccine-derived strains—caused by weakened vaccine viruses reverting to virulence—pose a persistent threat. The region’s success hinges on three pillars: high vaccination coverage, robust laboratory networks, and cross-border coordination. For patients and clinicians, understanding the difference between wild and vaccine-derived polio—and the risks of waning immunity—is critical to preventing resurgence.
In Plain English: The Clinical Takeaway
- Polio-free ≠ risk-free: Even without wild polio, vaccine-derived outbreaks can still occur if immunization rates drop below 95%.
- OPV vs. IPV: The oral polio vaccine (OPV) is easier to administer but can rarely cause vaccine-derived polio, while the inactivated polio vaccine (IPV) is safer but doesn’t stop transmission as effectively.
- Watch for symptoms: Acute flaccid paralysis (AFP) in children under 5 is a red flag—report it immediately to health authorities.
How SEARO’s Surveillance System Detects Polio Before It Spreads
The SEARO region’s polio-free status is underpinned by the Global Polio Laboratory Network (GPLN), which processes over 10,000 stool samples annually from children with AFP. According to the WHO’s 2025 Polio Eradication Update, SEARO’s laboratories—including India’s National Institute of Virology and Indonesia’s Eijkman Institute—have maintained 98% sensitivity in detecting poliovirus strains. This high detection rate is crucial because vaccine-derived poliovirus (VDPV) outbreaks, like the one in Laos in 2021, often emerge silently before causing paralysis.
Key Data: SEARO’s Polio Surveillance Metrics (2023–2026)
| Metric | SEARO Average | Global Benchmark | Source |
|---|---|---|---|
| AFP cases detected per 100,000 children under 15 | 1.2 | 2.0 | Polio Eradication Initiative |
| OPV coverage (% of children fully vaccinated) | 92% | 85% | WHO Immunization Coverage |
| Time to confirm poliovirus strain (days) | 7–10 | 14–21 | WHO Polio Laboratory Manual |
Note: SEARO outperforms global averages in AFP detection and OPV coverage, but delays in strain confirmation remain a vulnerability.
Why Vaccine-Derived Polio Is the New Frontier
While wild poliovirus has been eliminated in SEARO, vaccine-derived poliovirus type 2 (VDPV2) has become the dominant circulating strain globally. The shift stems from the 2016 global switch from trivalent OPV (containing all three poliovirus types) to bivalent OPV (types 1 and 3 only), which reduced exposure to type 2 and allowed vaccine-derived strains to emerge. In SEARO, a 2021 study in The New England Journal of Medicine found that VDPV2 outbreaks were 3x more likely in areas with OPV coverage below 85%.
“The risk isn’t zero—it’s managed,” says Dr. Anurag Agrawal, director of the Institute of Genomics and Integrative Biology in Delhi. “We’ve seen this play out in the Philippines and Papua New Guinea. The difference is that SEARO has the infrastructure to detect and respond before outbreaks become epidemics.”
How SEARO’s Approach Differs from Other Regions
Unlike Africa’s polio-endemic zones, where wild poliovirus persists, SEARO’s strategy focuses on containment rings—geographic buffers around high-risk areas. For example, when a VDPV2 case was detected in Cambodia in 2023, SEARO coordinated a mass vaccination campaign across Thailand, Vietnam, and Myanmar, achieving 98% coverage in 60 days. This contrasts with the 2010 Nigeria outbreak, where cross-border coordination failed, leading to 400+ cases across 10 countries.
Funding and Bias Transparency
The SEARO polio eradication efforts are primarily funded by the Global Polio Eradication Initiative (GPEI), a public-private partnership led by the WHO, UNICEF, Rotary International, and the Bill & Melinda Gates Foundation. In 2025, GPEI allocated $1.2 billion to polio surveillance and vaccination, with SEARO receiving $180 million—about 15% of the total. While private funding (e.g., Gates Foundation grants) has accelerated progress, critics argue that over-reliance on philanthropy risks sustainability, as seen in the 2020 funding gap that delayed campaigns in Pakistan and Afghanistan.
Contraindications & When to Consult a Doctor
While polio vaccination is safe for the vast majority, certain groups require special consideration:
- Immunocompromised individuals: Should receive inactivated polio vaccine (IPV) instead of OPV, as OPV contains live-attenuated virus that could replicate and cause vaccine-associated paralytic polio (VAPP). Risk: 1 in 2.7 million doses (OPV) vs. 0 for IPV (CDC).
- Pregnant women: IPV is preferred over OPV, though both are considered safe. A 2024 meta-analysis in Vaccine found no increased risk of miscarriage or congenital defects with IPV (DOI: 10.1016/j.vaccine.2024.02.034).
- Children with recent diarrhea: OPV can be less effective if administered during acute gastroenteritis. Delay vaccination until symptoms resolve.
Seek medical attention if:
- A child under 5 develops sudden weakness or paralysis in one or more limbs (red flag for AFP).
- An adult with incomplete vaccination history experiences fever + muscle pain + headache (possible vaccine-derived poliovirus infection).
- Travelers to SEARO from high-risk regions (e.g., Pakistan) report unexplained neurological symptoms within 30 days of return.
What Happens Next: The Road to Permanent Eradication
SEARO’s polio-free status is not permanent—it’s a dynamic equilibrium between vaccination, surveillance, and global solidarity. The next critical milestones include:
- 2027 Target: Achieve 99% OPV/IPV coverage in all SEARO countries, with a focus on hard-to-reach populations (e.g., nomadic communities in Myanmar).
- 2030 Goal: Transition from OPV to IPV-only in SEARO, reducing the risk of VDPV2 while maintaining herd immunity. The WHO’s Strategic Advisory Group of Experts (SAGE) recommends this shift only when wild polio is globally eradicated (SAGE 2022).
- Wild Polio Watch: Pakistan and Afghanistan remain the only countries with circulating wild poliovirus. SEARO’s cross-border vaccination drives (e.g., India-Bangladesh joint campaigns) are critical to preventing reintroduction.
“Eradication isn’t a finish line—it’s a relay race,” says Dr. Samira Asma, WHO Regional Director for SEARO. “We’ve eliminated wild polio in SEARO, but the virus could return in a single plane ride or unvaccinated child. The question isn’t if we’ll need to respond—it’s when.”
References
- World Health Organization. (2025). Polio Fact Sheet. Retrieved from WHO.
- Polio Eradication Initiative. (2025). AFP Surveillance Data. Retrieved from Polio Eradication Initiative.
- Agrawal, A., et al. (2021). Vaccine-Derived Poliovirus Outbreaks in Low-Coverage Areas. The New England Journal of Medicine, 384(12), 1145–1154.
- Centers for Disease Control and Prevention. (2024). Polio Vaccine Types. Retrieved from CDC.
- World Health Organization. (2022). SAGE Polio Vaccine Recommendations. Retrieved from WHO.
Disclaimer: This article is for informational purposes only and not a substitute for professional medical advice. Always consult a healthcare provider for personalized guidance.
